Historical review: Endothelin

Trends in Pharmacological Sciences

Volumn 25, Issue 4, 2004, Pages 219-224

  Masaki, Tomoh ^a  

^a Osaka Seikei University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; 1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; ANTIDIABETIC AGENT; ATROPINE; BE 18257 A; BENZENESULFONAMIDE DERIVATIVE; BOSENTAN; BUNAZOSIN; CALCIUM CHANNEL; CALCIUM ION; CARBOXYLIC ACID DERIVATIVE; COMPLEMENTARY DNA; CYCLO(DEXTRO GLUTAMYLALANYL DEXTRO VALYLLEUCYL DEXTRO TRYPTOPHYL); CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; NIFEDIPINE; PENTAPEPTIDE; PEPTIDE; PROPRANOLOL; SARAFOTOXIN; SULFONAMIDE; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT;

AMINO ACID SEQUENCE; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DNA SEQUENCE; ENDOTHELIUM CELL; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERTENSION; MOLECULAR BIOLOGY; MOLECULAR CLONING; NERVOUS SYSTEM DEVELOPMENT; NEURAL CREST; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; ENDOTHELINS; HISTORY, 20TH CENTURY; HUMANS; MOLECULAR BIOLOGY; RECEPTORS, ENDOTHELIN;

EID: 1942453322     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2004.02.008     Document Type: Review

References (50)

1. Fleming I., Busse R. NO: the primary EDRF. J. Mol. Cell. Cardiol. 31:1999;5-14.
2. Hickey K.A., et al. Characterization of coronary vasoconstrictor produced by cultured endothelial cells. Am. J. Physiol. 248:1985;C550-C556.
3. Yanagisawa M., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
4. Inoue A., et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U. S. A. 86:1989;2863-2867.
5. Sokolovsky M., Shraga-Levine Z. Sarafotoxins and their relationship to the endothelin family of peptides. Warner T.D. Endothelin and its Inhibitors. 2001;11-34 Springer.
6. Arai H., et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 348:1990;730-732.
7. Sakurai T., et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 348:1990;732-735.
8. Masaki T., et al. International union of pharmacology nomenclature of endothelin receptor. Pharmacol. Rev. 46:1994;137-142.
9. Douglas S.A., et al. Pharmacologic evidence for the presence of three functional endothelin receptor subtypes in rabbit saphenus vein. J. Cardiovasc. Pharmacol. 26:(Suppl. 3):1995;S163-S168.
10. Elliott J.D., Xiang J.N. Endothelin receptor antagonists. Warner T.D. Endothelin and its Inhibitors. 2001;239-270 Springer.
11. A receptor. Life Sci. 50:1992;247-255.
12. Ishikawa K., et al. Biochemical and pharmacological profile of a potent and selective endothelin-B receptor antagonist, BQ-788. Proc. Natl. Acad. Sci. U. S. A. 91:1994;4892-4896.
13. Clozel M., et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 365:1993;759-761.
14. Clozel M., et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270:1994;228-235.
15. Stein P.D., et al. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3, 4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide. J. Med. Chem. 37:1994;329-331.
16. Shimada K., et al. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J. Biol. Chem. 269:1994;18275-18278.
17. Xu D., et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 78:1994;473-485.
18. Schmidt M., et al. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett. 356:1994;238-243.
19. Coder R. Identity of endothelin-converting enzyme and other targets for the therapeutic regulation of endothelin biosynthesis. Warner T.D. Endothelin and its Inhibitors. 2001;35-67 Springer.
20. Battistini B., Jeng A.Y. Endothelin-converting enzyme inhibitors and their effects. Warner T.D. Endothelin and its Inhibitors. 2001;155-208 Springer.
21. Emoto N., Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphramidon-sensitive metalloprotease with acidic pH optimum. J. Biol. Chem. 270:1995;15262-15268.
22. Yanagisawa H., et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J. Clin. Invest. 105:2000;1373-1382.
23. Masaki T., et al. Subcellular mechanisms of endothelin action in vascular system. Eur. J. Pharmacol. 375:1999;133-138.
24. Miwa S., et al. Ca2+entry channels in rat thoracic aortic smooth muscle cells activated by endothelin-1. Jpn. J. Pharmacol. 80:1999;281-288.
25. Mao J., et al. Specific involvement of G proteins in regulation of serum response factor-mediated gene transcription by different receptor. J. Biol. Chem. 273:1998;27118-27123.
26. Simonson M.S. Cell signaling by endothelin peptides. Warner T.D. Endothelin and its Inhibitors. 2001;115-140 Springer.
27. Douglas S.A., Ohlstein E.H. Vascular and Cardiac effects of endothelin. Warner T.D. Endothelin and its Inhibitors. 2001;405-451 Springer.
28. Leslie S.J., Webb D.J. Endothelin ligands and their experimental effects within the human circulation. Warner T.D. Endothelin and its Inhibitors. 2001;503-520 Springer.
29. Douglas S.A., et al. Novel receptor antagonists welcome a new era in endothelin biology. Trends Pharmacol. Sci. 15:1994;313-316.
30. Mizuguchi T., et al. Analysis of two pharmacologically predicted endothelin B receptor subtypes by using the endothelin B receptor gene knockout mouse. Br. J. Pharmacol. 120:1997;1427-1430.
31. Haynes W.G., et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation. 93:1996;1860-1870.
32. Verhaar M.C., et al. Endothelin A receptor antagonist mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation. 97:1998;752-756.
33. Kurihara Y., et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 368:1994;703-710.
34. Kuwaki T., et al. Physiological role for brain endothelin in the central autonomic control from neuron to knockout mouse. Prog. Neurobiol. 51:1997;545-579.
35. Ohuchi T., et al. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am. J. Physiol. 276:(4 Pt 2):1999;R1070-R1077.
36. Kurihara H., et al. Lessons from gene deletion of endothelin systems. Warner T.D. Endothelin and its Inhibitors. 2001;141-154 Springer.
37. Clouthier D.E., et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development. 125:1998;813-824.
38. Baynash A.G., et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell. 79:1994;1277-1285.
39. Puffenberger E.G., et al. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell. 79:1994;1257-1266.
40. Hosoda K., et al. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell. 79:1994;1267-1276.
41. Sakai S., et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384:1996;353-355.
42. Kiowski W., et al. Hemodynamic effects of bosentan in patients with chronic heart failure. Heart Fail. Rev. 6:2001;325-334.
43. Torre-Amione G., et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. 42:2003;140-147.
44. Krum H., et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. New Engl. J. Med. 338:1998;784-790.
45. Nakov R., et al. Darsentan:an effective endothelin A receptor antagonist for treatment of hypertension. Am. J. Hypertens. 15:2002;583-589.
46. Stewart D.J., Zhao Y.D. Endothelin-1 and pulmonary hypertension. Warner T.D. Endothelin and its Inhibitors. 2001;389-404 Springer.
47. Channick R.N., et al. Effect of dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Lancet. 358:2001;1119-1123.
48. Rubin L.J., et al. Bosentan therapy for pulmonary arterial hypertension. New Engl. J. Med. 346:2002;896-903.
49. Sitbon O., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a 1-year follow-up study. Chest. 124:2003;247-254.
50. Sakurai T., et al. Molecular characterization of endothelin receptor. Trends Pharmacol. Sci. 13:1992;103-108.